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Research
Manganese (Mn) is an essential trace element 
important for neuronal function; however, 
excessive exposure to Mn has been associated 
with a severe movement disorder known as 
manganism. The clinical manifestations of 
Mn poisoning pertain to an extra  pyramidal 
syndrome with a pattern similar, but not 
identical, to Parkinson’s disease (PD). The 
signs and symptoms frequently include action 
tremor with absence or low level of resting 
tremor, hypertonia, and adiadocho  kinesia. 
In severe cases, gait disturbance is observed. 
Furthermore, Mn neurotoxicity has been 
linked to distorted mental function, includ-
ing memory loss, apathy, and even psycho-
sis (Aschner et al. 2007; Calne et al. 1994; 
Crossgrove and Zheng 2004; Jiang et al. 
2006). Occupational exposure to Mn, such 
as from ore extraction and processing, steel 
and alloy production, welding, chemical syn-
thesis, ceramic production, and dry-battery 
fabrication, is a common source of Mn poi-
soning. Because Mn-induced neuro  toxicity is 
an important occupational health risk, there 
is an urgent demand for establishing effective 
techniques for early diagnosis of mangan-
ism. We hypothesize that pathogenic markers 
of Mn neuro  toxicity reflecting metabolic or 
excito  toxic insults, such as changes in neuro-
transmitter levels or other brain metabolites, 
likely occur before structural damage.
Mn is known to accumulate most promi-
nently in the globus pallidus (Dorman et al. 
2006; Guilarte et al. 2006a; Jiang et al. 2007). 
It can be visualized by increased signal intensity 
in the globus pallidus of occupationally exposed 
workers in T1-weighted magnetic resonance 
imaging (MRI) (Dietz et al. 2001; Jiang et al. 
2007; Kim et al. 1999; Lucchini et al. 2000; 
Nelson et al. 1993). A common approach to 
quantifying this change in signal contrast is the 
definition of the pallidal index (PI), the ratio 
between the signal intensity within the globus 
pallidus and a control region, commonly cho-
sen as sub  cortical frontal white matter (Krieger 
et al. 1995). However, brain regions outside 
the basal ganglia, such as frontal cortex, have 
also been reported to be affected by Mn and 
to exhibit neuro  degenerative changes (Guilarte 
et al. 2008).
To investigate the effects of Mn on brain 
chemistry, we used magnetic resonance spec-
troscopy (MRS) to measure the concentra-
tions of the metabolites N-acetylaspartate 
(NAA; a marker of general neuronal func-
tion), total creatine (tCr; involved in energy 
metabolism), choline-containing compounds 
(Cho; an indicator of cell membrane integ-
rity), myo-inositol (mI; a glial cell marker), 
and glutamate (Glu; an excitatory neuro-
transmitter). Furthermore, MEGA-PRESS 
(Mescher et al. 1998), a special MRS editing 
technique, allows for enhanced assessment of 
the small resonances of γ-aminobutyric acid 
(GABA) (Edden and Barker 2007).
Several in vitro and in vivo rodent studies 
have linked increased Mn exposure to altera-
tions in concentrations and metabolism of 
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Ba c k g r o u n d: Exposure to excessive levels of manganese (Mn) is known to induce psychiatric and 
motor disorders, including parkinsonian symptoms. Therefore, finding a reliable means for early 
detection of Mn neurotoxicity is desirable.
oBjectives: Our goal was to determine whether in vivo brain levels of γ-aminobutyric acid 
(GABA), N-acetylaspartate (NAA), and other brain metabolites in male smelters were altered as a 
consequence of Mn exposure.
Me t h o d s : We used T1-weighted magnetic resonance imaging (MRI) to visualize Mn deposition 
in the brain. Magnetic resonance spectroscopy (MRS) was used to quantify concentrations of NAA, 
glutamate, and other brain metabolites in globus pallidus, putamen, thalamus, and frontal cortex 
from a well-established cohort of 10 male Mn-exposed smelters and 10 male age-matched control 
subjects. We used the MEGA-PRESS MRS sequence to determine GABA levels in a region encom-
passing the thalamus and adjacent parts of the basal ganglia [GABA-VOI (volume of interest)].
re s u l t s: Seven of 10 exposed subjects showed clear T1-hyperintense signals in the globus pal-
lidus indicating Mn accumulation. We found a significant increase (82%; p = 0.014) in the ratio of 
GABA to total creatine (GABA/tCr) in the GABA-VOI of Mn-exposed subjects, as well as a distinct 
decrease (9%; p = 0.04) of NAA/tCr in frontal cortex that strongly correlated with cumulative Mn 
exposure (R = –0.93; p < 0.001).
co n c l u s i o n s: We demonstrated elevated GABA levels in the thalamus and adjacent basal ganglia 
and decreased NAA levels in the frontal cortex, indicating neuronal dysfunction in a brain area not 
primarily targeted by Mn. Therefore, the non    invasive in vivo MRS measurement of GABA and NAA 
may prove to be a powerful tool for detecting presymptomatic effects of Mn neuro  toxicity.
key w o r d s : GABA, imaging, manganese, metabolism, MRI, MRS, NAA, occupational health, 
parkinsonism, smelters. Environ Health Perspect 119:219–224 (2011).  doi:10.1289/ehp.1002192 
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neuro  transmitters, in particular, dopamine, 
GABA, and Glu (Burton and Guilarte 
2009). Findings of GABAergic alterations 
are conflicting. Early in vitro studies reported 
increased striatal GABA levels in Mn-exposed 
rodents (Bonilla 1978; Gianutsos and Murray 
1982); these are supported by later work that 
correlates Mn exposure with increased brain 
GABA concentrations (Gwiazda et al. 2002; 
Lipe et al. 1999; Reaney et al. 2006). Other 
groups, however, have failed to corroborate 
these studies, reporting decreased GABA lev-
els upon Mn exposure (Brouillet et al. 1993; 
Chandra et al. 1982; Erikson et al. 2002; Seth 
et al. 1981) or no association between GABA 
levels and Mn exposure (Bonilla et al. 1994).
In non  human primates with high expo-
sure to Mn, Guilarte et al. (2006b) found an 
intact but dysfunctional nigro  striatal dopamin-
ergic system. Subsequent studies in non  human 
primates found no evidence that chronic Mn 
exposure alters total levels of dopamine, Glu, 
or GABA (Burton et al. 2009; Struve et al. 
2007). In contrast, in post  mortem tissue stud-
ies, elevated GABA levels in PD are well estab-
lished. For example, Kish et al. (1987) reported 
above-normal GABA levels in the PD striatum, 
especially in the posterior putamen, which cor-
related inversely with reduced dopamine levels.
The present study, to our knowledge, is the 
first to investigate the effect of Mn exposure 
on GABA concentrations in the living human 
brain. Our objectives were a) to determine 
the concentrations of active metabolites such 
as NAA (a neuronal marker) in selected brain 
regions of Mn-exposed subjects compared with a 
control group; b) to determine whether chronic 
Mn exposure in humans alters GABA levels; and 
c) to correlate all of the MRS parameters and the 
PI as measured by MRI to external indices of 
Mn exposure, such as cumulative Mn exposure.
Materials and Methods
Subjects, air sampling, and physiological tests. 
Twenty male subjects were recruited out of 
a large, well-studied cohort of workers from 
a Mn-iron (Mn-Fe) alloy factory in Zunyi, 
China. The average airborne MnO2 concentra-
tion in the current daily working environment 
of both the exposed and the control group, as 
well as the working history and medical history 
of all subjects, were determined in a previous 
study (Cowan et al. 2009). Air samples were 
collected over > 10 working shifts on 3 consec-
utive days for each work environment. Cowan 
et al. (2009) provided a more detailed descrip-
tion of the air sampling procedure and the 
data. Since the study by Cowan et al. (2009), 
the working conditions have not changed for 
these subjects. For the MRI and MRS study, 
we chose a group of 10 Mn-exposed smelt-
ers (mean age, 40.7 years; average airborne 
MnO2, 0.18 mg/m3; mean years of occu-
pational exposure, 7.8 years), exposed on a 
daily basis at the time of the MRI study, and 
10 male age-matched control subjects with no 
history of Mn exposure (mean age, 43.4 years; 
mean airborne Mn exposure, 0.003 mg/m3). 
We defined the “cumulative Mn exposure” 
as the product of average airborne MnO2 
concentration of each group × years of occu-
pational exposure × volume of inhaled air. 
Written informed consent was obtained from 
each subject before participation, and the 
study was approved by institutional review 
boards both in China and the United States.
The 20 subjects were brought to the 
First Affiliated Hospital of Guangxi Medical 
University on a weekend day, where urine 
and blood tests, as well as neuro  logical and 
physiological tests, were performed directly 
before the MRI examination. In particular, 
Mn, Fe, and copper (Cu) levels were meas-
ured in urine, blood plasma, and red blood 
cells, and pulse rate and blood pressure were 
determined. All subjects were evaluated by 
a neurologist (X.A.M.), who specializes in 
PD, for clinical manifestation of manganism, 
after clinical assessment tests for PD (tremor, 
rigidity, bradykinesia, and postural instabil-
ity) using the motor exam tests suggested by 
the Unified Parkinson’s Diseases Rating Scale 
(UPDRS) Development Team (Fahn et al. 
1987). Because no symptoms were identified 
in any of the study participants, we did not 
perform UPDRS scoring in this study.
MRI and image analysis. All MRI measure-
ments were performed on a 3 T Philips Achieva 
whole-body clinical scanner (Philips Healthcare, 
Best, the Netherlands) equipped with an eight-
channel head coil. Fast T2-weighted images 
were acquired in all three orientations for exact 
planning of the spectroscopy volumes of inter-
est (VOIs) and for delineation of the globus 
pallidus, which shows up dark in T2-weighted 
images because of its high Fe content. A high-
resolution (1 mm × 1 mm × 1.5 mm3 pixel) 
T1-weighted three-dimensional (3D) fast- 
gradient echo scan [repetition time (TR) = 
9.7 msec; echo time (TE) = 4.6 msec; 120 
slices; field of view = 240 × 240 × 150 mm3; 
SENSE factor 2] covering the whole head 
was acquired for image segmentation and for 
detailed analy  sis of the areas showing hyper-
intensities due to Mn deposition in the brain. 
The resulting 3D T1-weighted images were 
reconstructed in all three dimensions and 
inspected for hyperintense signal in the basal 
ganglia (Figure 1). These images were also used 
to calculate the PI based on the signal ratio 
between a region of interest (ROI) within the 
globus pallidus and an ROI from white matter 
in the frontal lobe (Figure 1B).
MRS, GABA editing, and spectral data 
analysis. In addition to imaging, short-TE 
single-voxel spectra (PRESS locali  za  tion;   
Figure 1. (A) Representative axial, coronal, and sagittal T1-weighted MRI brain images of a subject from 
the Mn-exposed group, depicting the hyperintense signal associated with brain Mn deposition. (B) ROIs 
used for the determination of the PI. (C) Distribution of the PI values for all 10 exposed subjects and all 10 
control subjects. Abbreviations: GP, globus pallidus; WM, white matter. 
WM
GP
1.6
1.5
1.4
1.3
1.2
1.1
1
P
I
Mn-exposed
ControlMRS of GABA in occupational Mn exposure
Environmental Health Perspectives  •  v o l u m e  119 | n u m b e r 2 | February 2011  221
TR/TE = 1,500 msec/30 msec; CHESS water 
suppression) were acquired from five different 
VOIs in each subject: frontal cortex (8 mL VOI, 
96 averages), putamen (4 mL VOI, 128 aver-
ages), globus pallidus (4.5 mL VOI, 176 aver-
ages), thalamus (4.5 mL VOI, 128 averages), 
and a larger voxel, the GABA-VOI, centered 
on the thalamus but also containing the pos-
terior parts of the putamen and globus pal-
lidus, as well as parts of the substantia nigra 
(26.25 mL, 32 averages) [see Supplemental 
Material, Figure 1 (doi:10.1289/ehp.1002192)]. 
Figure 2A shows the locations of the five VOIs. 
For each voxel, a reference spectrum was 
acquired without water suppression that was 
later used for phase and frequency correction of 
the corresponding water-suppressed spectrum. 
Shimming and other preparation phases were 
performed fully automatically, resulting in line 
widths of < 10 Hz for the unsuppressed water 
peak for all spectra.
The larger volume of the GABA-VOI was 
necessary for the detection of GABA concentra-
tions on the order of 1 mM. The current state-
of-the-art technique to detect metabolites such 
as GABA, whose MRS peaks are overshadowed 
by much larger peaks in conventional MRS, 
is the homonuclear MEGA-PRESS J-editing 
sequence (Mescher et al. 1998). This tech-
nique, when adapted for GABA (Edden 
and Barker 2007; Waddell et al. 2007), 
eliminates most of the over  lapping signal and 
allows for much more accurate detection of 
GABA. The MEGA-PRESS technique and 
subsequent processing are described in detail 
in the Supplemental Material (doi:10.1289/
ehp.1002192). MEGA-PRESS optimized 
for GABA detection (TR = 2,000 msec; 
TE = 68 msec) has been validated in several 
clinical studies (e.g., Bhagwagar et al. 2007; 
Edden et al. 2009; Öz et al. 2006; Tayoshi 
et al. 2010) and was included in the present 
study in addition to the short TE single-voxel 
scans to investigate changes in GABA con-
centrations. We acquired 256 averages, half 
with the MEGA-PRESS editing pulse cen-
tered at 1.9 ppm and half with the pulse cen-
tered at 7.6 ppm in an interleaved fashion. See 
Supplemental Material, Figure 2 (doi:10.1289/
ehp.1002192) for a representative GABA-
edited spectrum compared with the short TE 
spectrum from the same VOI.
All MRS data processing was performed 
with LCModel (Provencher 1993), a spectral 
quantification tool that fits each spectrum as 
a weighted linear combination of basis spectra 
from individual brain metabolites. LCModel 
also provides an estimated relative standard 
deviation (%SD) for each metabolite as a 
meas  ure of the believability of the concen-
tration values reported. It has recently been 
used with MEGA-PRESS to measure GABA 
concentrations in schizophrenics (Tayoshi et al. 
2010) and in depressed and bipolar subjects 
(Bhagwagar et al. 2007). For the short-TE 
data, we used a basis set of in vitro spectra 
from individual metabolite solutions; only fit-
ting results with %SD < 25% were used for 
further statistical analysis. For the MEGA-
PRESS spectra, basis sets were generated from 
density matrix simulations of the sequence 
using published values for chemical shifts and 
J-couplings (Govindaraju et al. 2000). The 
difference basis set included GABA, Glu, glu-
tamine, glutathione, and NAA.
A known issue with estimating GABA 
concentrations from difference spectra is the 
presence of coedited macromolecule (MM) 
signal at 3.0 ppm, a broad signal that underlies 
the GABA resonance at this frequency, creat-
ing a potential source of error. We used two 
different approaches to model its effect and 
obtain GABA concentrations, yielding esti-
mates for upper and lower limits on the “true” 
GABA concentration. For method 1, we did 
not explicitly include the potential confound 
of an MM signal at 3.0 ppm in the LCModel 
processing (the approach used by Tayoshi et al. 
2010). The resulting LCModel fits have satis-
fyingly small %SDs for GABA, but the con-
centrations are probably over  estimated. For 
method 2, an extra Gaussian peak at 3.0 ppm 
(“MM30”) was added to the LCModel 
Figure 2. (A) VOI locations and (B–F) representative TE 30 spectra for thalamus (blue box; B), frontal cortex (red box; C), GABA-VOI [a larger basal ganglia region 
chosen for GABA measurements containing mainly thalamic tissue, but also putamen and globus pallidus (orange box; D)], globus pallidus (green box; E), and 
putamen (yellow box; F). (G) A TE 68 MEGA-PRESS difference spectrum from the GABA-VOI. All spectrum amplitudes are in institutional units, and plots were indi-
vidually scaled to fill display boxes. The x-axis shows the chemical shift (or resonance frequency) in parts per million. The range displayed is 0.3–4.0 ppm. 
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calculation to explicitly fit the macromolecular 
signal (a simpler version of the technique used 
by Bhagwagar et al. 2007).
For all spectra (PRESS as well as MEGA-
PRESS), metabolite levels were expressed as a 
ratio of metabolite to tCr. In the case of the 
GABA-edited spectra, the reference values for 
tCr were taken from the average of the spectra 
with the MEGA-PRESS pulse centered at 
7.6 ppm (thus not affecting the tCr peak at 
3:02 ppm). 
Statistics. All data are expressed as mean ± 
SD. We compared means between Mn-exposed 
and control groups using a two-tailed Student 
t-test with Welch correction for unequal vari-
ances. Correlation analysis was conducted and 
Spearman coefficients were obtained accord-
ingly using SPSS/PC+ for Windows (version 
13.0; IBM Corporation, Somers, NY, USA). 
Results
No study participant showed clinical symp-
toms or signs of PD or manganism in any of 
the tests performed. All 20 subjects were able 
to finish the full study, and all imaging and 
spectroscopy data acquired were of adequate 
quality to be included in the analysis. Of the 
various internal exposure parameters (Fe, 
Mn, and Cu in blood and urine), only Cu in 
urine showed a significant group difference 
between the smelters and the control group 
(p = 0.013), with the smelters having higher 
levels. All other meas  ures had group difference 
p-values > 0.1; see Supplemental Material, 
Table 1 (doi:10.1289/ehp.1002192).
MRI and PI. Seven of 10 exposed subjects 
showed a clearly hyper  intense signal in the 3D 
T1-weighted images, revealing Mn deposition 
in the brain. As illustrated in Figure 1, the T1 
shortening caused by Mn deposition was most 
prevalent in the globus pallidus and adjacent 
brain regions.
As expected, a significant group difference 
between the exposed and non  exposed subjects 
was identified for the PI (p = 0.007). However, 
no cut  off value could be established to classify 
subjects exclusively to the exposed or non-
exposed group using the PI. For example, if 
a cut  off value of 1.2 is chosen, seven exposed 
subjects are correctly identified and only one 
control is wrongly identified as an Mn-exposed 
worker (Figure 1C).
Short-TE MRS. Spectral data quality was 
high (line width < 10 Hz, no artifacts) in 
all 120 short-TE spectra from the five brain 
locations Figure 2B–F shows typical spec-
tra from each VOI. Table 1 lists the ratios of 
NAA, Cho, mI, Glu, and Glx (Glu + glu-
tamine) to tCr as reported by LCModel from 
the exposed and non  exposed subjects. The 
only significant group difference was in the 
frontal cortex: NAA/tCr was significantly 
lower in the exposed group than in the con-
trol group (p = 0.04; Figure 3B), and the 
value decreased as the cumulative Mn expo-
sure increased (for the Mn-exposed group 
alone, R = –0.93, p < 0.001; for all subjects, 
R = –0.75, p < 0.001; Figure 3C). Although 
there appeared to be a trend for a decrease in 
NAA/tCr in the globus pallidus of the exposed 
group, this decrease was not statistically signif-
icant, because 5 of 20 NAA results from these 
inherently broader spectra had %SD values 
from LCModel ≥ 25% and were thus excluded 
from the calculation. We found no NAA 
changes (i.e., group differences or correlation 
to other internal or external parameters of 
exposure indices) in thalamus or putamen, nor 
were the levels of other metabolites (Cho, mI, 
Glu, or Glx) significantly altered in any of the 
examined brain areas.
GABA MRS. Figure 2G shows the 
LCModel fit of a GABA-edited spectrum 
from the 26 mL VOI centered on the thala-
mus (GABA-VOI). LCModel results for 
GABA/tCr from the MEGA-PRESS spectra 
are summarized in Table 1 for both method 1 
(GABA fit without explicit consideration of 
MMs at 3.0 ppm) and method 2 (processing 
that included an extra macromolecular peak 
at 3.0 ppm). For both methods, a Student 
t-test revealed a statistically significant dif-
ference (p < 0.05) between the Mn-exposed 
and control subjects for the raw GABA signal 
and for GABA/tCr. The average GABA con-
centration was approximately 50% higher in 
Mn-exposed workers than in controls using 
method 1, and it was approximately 80% 
higher using method 2. Estimates for GABA 
concentrations from method 1, assuming 
[tCr] = 6.0 mM in the thalamus (Geurts et al. 
2004), were 1.32 mM for the Mn-exposed 
group and 0.90 mM for the controls. With an 
MM30 model peak added in method 2, the 
average GABA concentration was reduced to 
0.62 mM for the Mn-exposed group and to 
0.34 mM for the controls (Figure 3A).
In contrast to the marked difference in 
GABA values between Mn-exposed and con-
trol workers, the LCModel results for the 
MM30 peak in method 2 were consistent for 
all subjects, suggesting that MM levels are not 
appreciably altered by Mn exposure. We saw 
the same consistency in the MEGA-PRESS 
Glu results (data not shown).
Discussion
The nature of the involvement of GABA and 
Glu in Mn neuro  toxicity remains unknown. 
This study, for the first time, employs a non-
invasive MRI/MRS technique to quantify the 
GABA and Glu concentrations in the living 
brain of smelters exposed to airborne Mn in 
an occupational environment. Based on the 
data acquired, we observed that brain GABA 
levels are significantly increased in these work-
ers versus matched controls in a brain volume 
encompassing the thalamus and parts of the 
basal ganglia, such as the posterior putamen 
and posterior parts of the globus pallidus. 
Furthermore, NAA levels in the frontal cor-
tex decrease as a function of cumulative Mn 
exposure. Although none of the examined 
subjects showed any clinical symptoms of 
parkin  sonism or motor deficits, the dramati-
cally increased GABA levels in the thalamus 
and basal ganglia together with the decreased 
NAA levels in the frontal cortex likely reflect 
early metabolic or possibly pathological 
changes of Mn exposure.
Table 1. Metabolite concentration ratios from five brain regions. 
GABA/tCra
Brain region NAA/tCrb Cho/tCrb mI/tCrb Glx/tCrb Glu/tCrb  Method 1 Method 2
GABA-VOI
Smelters 1.12 ± 0.08 0.30 ± 0.02 0.68 ± 0.09 0.82 ± 0.07 0.78 ± 0.05 0.22 ± 0.06 0.10 ± 0.03
Controls 1.12 ± 0.08 0.31 ± 0.02 0.76 ± 0.14 0.82 ± 0.10 0.77 ± 0.10 0.15 ± 0.07 0.06 ± 0.04
Percent change 0 –3.2 –10.5 0 1.3 47 82c
p-Valued 0.028 0.014
Thalamus
Smelters 1.01 ± 0.10 0.28 ± 0.03 0.63 ± 0.13 1.35 ± 0.28 1.01 ± 0.15
Controls 1.00 ± 0.15 0.30 ± 0.04 0.61 ± 0.10 1.19 ± 0.35 0.90 ± 0.20
Percent change 1.0 –6.7 3.3 13.5 12.2
Putamen
Smelters 0.71 ± 0.11 0.27 ± 0.04 0.53 ± 0.09 1.79 ± 0.32 1.14 ± 0.17
Controls 0.63 ± 0.14 0.26 ± 0.02 0.48 ± 0.07 1.86 ± 0.33 1.18 ± 0.12
Percent change 12.7 3.9 10.4 –3.8 –3.4
Globus pallidus
Smelters 0.75 ± 0.22 0.26 ± 0.03 0.45 ± 0.17 1.35 ± 0.49 1.03 ± 0.22
Controls 0.63 ± 0.17 0.24 ± 0.03 0.51 ± 0.10 1.36 ± 0.37 0.99 ± 0.24 
Percent change 19.1 8.3 –11.8 –0.7 4.0
Frontal cortex
Smelters 1.03 ± 0.11 0.32 ± 0.04 0.93 ± 0.16 1.48 ± 0.32 1.19 ± 0.18
Controls 1.13 ± 0.10 0.31 ± 0.02 0.88 ± 0.10 1.54 ± 0.17 1.24 ± 0.17
Percent change –8.9 3.2 5.7 –3.9 –4.0
p-Valued 0.042
aFrom TE 68 MEGA-PRESS spectra. bFrom short-TE spectra. cAll percent changes were calculated from ratio values 
before rounding, in this case, 0.104/0.057. dp-Values were calculated using a two-tailed Student t-test. MRS of GABA in occupational Mn exposure
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Although the effect of Mn exposure on 
the GABAergic system has been investigated 
both in vitro and in vivo on rodent models, 
the results are contradictory. In non  human 
primate models, no changes in GABA were 
found (Burton et al. 2009; Struve et al. 2007). 
Notably, these studies assessed GABA levels 
ex vivo. The differences in Mn exposure para-
digms, temporal relations, or species, as well as 
the differences in the methods used for GABA 
quantification, may account for the large 
variations in the results. In the present study, 
we used the MEGA-PRESS MRS technique, 
which allows for the specific detection of the 
small GABA MRS signal in vivo. Although 
MEGA-PRESS has been used for human 
studies by other groups (e.g., Bhagwagar et al. 
2007; Edden et al. 2009, Tayoshi et al. 2010), 
quantification of GABA is not straightforward 
or well established. It is known that signal from 
coedited MMs contributes to the GABA peak 
at 3.0 ppm in the edited spectra, but because 
it is not trivial to eliminate this source of error 
completely, often only “GABA+” ( = GABA 
plus coedited moieties) is reported. For this 
study, we used a more accurate approach and 
fitted all of the GABA resonances in the spec-
trum using prior knowledge of the exact spin 
evolution and spectral signature of the GABA 
multi  plets for the MEGA-PRESS sequence, 
and we compared two processing schemes: 
relying on the LCModel baseline function 
to handle the MM contribution at 3.0 ppm 
(method 1), and including a new separate MM 
peak in the fit (method 2). Consistently small 
p-values strongly suggest that GABA is indeed 
increased in the basal ganglia of Mn-exposed 
subjects. GABA concentrations obtained from 
method 2 were reduced by roughly a factor 
of 2 relative to method 1, in agreement with 
reports that the contribution of the macro-
molecular signal is about 50% of the total 
signal at 3.0 ppm (Hetherington et al. 1998; 
Rothman et al. 1993).
Although the mean airborne Mn level for 
the exposed smelters was only 0.18 mg/m3,   
which is slightly below the American 
Conference of Governmental Industrial 
Hygienists (ACGIH) threshold limit value 
of 0.2 mg/m3, we observed nearly doubled 
GABA concentrations in the Mn-exposed 
smelters in a region encompassing mainly the 
thalamus, but also the posterior parts of the 
putamen and the globus pallidus. The mecha-
nisms associated with changes in GABA levels 
that are inherent to chronic Mn exposure are 
presently unknown. The observed increases 
in GABA levels corroborate observations by 
others of high GABA concentrations in the 
striatum of PD patients ex vivo (Hornykiewicz 
2001; Kish et al. 1987) and increases in striatal 
GABA levels in animal models of PD, such 
as 6-hydroxydopamine (6-OHDA) (Bruet 
et al. 2003; Lindefors 1993). Changes in 
GABAergic neuro  transmission in PD patients 
and 6-OHDA rats suggest that PD motor 
sign expression may depend on increases in 
striatal GABAergic neuro  transmission. Striatal 
GABA originates from two distinct popu-
lations of neurons: medium spiny neurons 
expressing local and close axonal collaterals, 
and inter  neurons that strongly inhibit striatal 
neuron projections (Plenz 2003). Accordingly, 
these inter  neurons seem to generate a strong 
inhibitory feedback, decreasing striatal out-
put activity. Although the role of GABA in 
manganism has yet to be clearly delineated, 
the observation of a Mn-induced increase in 
thalamic GABA levels among Mn-exposed 
smelters should prompt additional in-depth 
investigation on the mechanisms associated 
with this change. As recently suggested by 
Guilarte (2010), Mn-induced motor dysfunc-
tion reflects altered mechanisms of presynap-
tic dopamine release rather than its synthesis 
and may be distinct from mechanisms associ-
ated with PD. Given that we did not study 
dopamine homeostasis in the present cohort 
of smelters, future studies should systemati-
cally address the effects of Mn on the dop-
aminergic system as well, to further delineate 
temporal changes, or lack thereof, between 
GABA and other neuro  transmitter systems. In 
addition, improving the sensitivity of GABA-
edited MRS to enable the use of smaller vol-
umes is desirable to more precisely pinpoint 
brain locations with altered GABA levels. The 
finding of no significant changes for any other 
metabolites in the basal ganglia is consistent 
with an earlier MRS study performed on 
Mn-exposed welders by Kim et al. (2007).
Although the frontal cortex has not been 
characterized as a target of Mn neuro  toxicity, 
it has been shown that Mn also readily accu-
mulates in this region, although to a lesser 
degree than in the globus pallidus (Bock et al. 
2008; Dorman et al. 2006; Guilarte et al. 
2008). We found a reduced concentration of 
NAA (a marker of neuronal viability) in the 
frontal cortex of smelters and an inverse cor-
relation with cumulative Mn exposure. These 
results in humans corroborate the findings of 
neuro  degenerative changes in this brain region 
in Mn-exposed non  human primates (Guilarte 
et al. 2008), as well as reduced NAA levels 
measured by MRS in the parietal cortex from 
the same non  human primates (Guilarte et al. 
2006a). Furthermore, the early phase of Mn 
intoxication involves psychiatric and cognitive 
effects that might be mediated by the fron-
tal cortex and sub  cortical structures (Josephs 
et al. 2005). Notably, NAA/tCr changes as 
a function of cumulative Mn exposure are 
observable at Mn air levels below the ACGIH 
limit, consistent with early presymptomatic 
neuronal dysfunction. These findings suggest 
that measurements of cortical NAA levels may 
prove to be a valuable biomarker of the effect 
of Mn exposure.
It should be noted, however, that Chang 
et al. (2009) studied frontal gray matter in 
Mn-exposed welders using MRS and, contrary 
to our study, observed no changes in NAA/tCr. 
Moreover, they found significantly reduced 
mI that correlated with verbal memory score 
and blood Mn concentrations. In contrast, we 
observed no other changes in metabolite ratios. 
Although the MRS acquisition method (short-
TE PRESS sequence at 3 T), the location of 
the frontal cortex VOI, the apparent quality of 
the MRS data, and the data analysis technique 
(LCModel) are very similar between the two 
studies, other technical differences could easily 
account for the differences in results, especially 
for reported changes in metabolite concentra-
tions of only 10–20%, as is the case for the 9% 
drop in NAA reported in our study and for the 
20% decrease in mI reported by Chang et al. 
(2009).
Although the hyperintense signal in the 
globus pallidus is an unambiguous marker for 
Mn exposure in a single subject, not all exposed 
subjects exhibit such a hyper  intense signal. 
Our previous study found a 78% occurrence 
of intensified PI in Mn-exposed workers and 
an 85% occurrence in highly exposed workers 
(Jiang et al. 2007). In the present study, we 
saw hyperintense signal and thus increased PI 
values in 7 of 10 subjects from the exposed 
group, which is similar to our previous findings 
Figure 3. Significant metabolite concentration changes between Mn-exposed smelters and controls. 
(A) GABA concentration from the GABA-VOI quantified with LCModel using method 2, as described in 
“Materials and Methods” (p = 0.014). (B) NAA concentration in frontal cortex (p = 0.042). (C) Correlation 
between NAA/tCr in the frontal cortex and cumulative Mn exposure for the smelter group (R = –0.93; 
p < 0.001). 
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considering the small sample size (n = 10). 
Interestingly, the three subjects not showing 
any hyper  intense signal did not stand out 
by any other measure: Years of occupational 
Mn exposure and cumulative Mn exposure 
in these three subjects spanned the full range 
(1 year, 459 mg; 10 years, 4,588 mg; 12 years, 
5,505 mg). The mechanism that either protects 
their brain from Mn accumulation or masks 
the T1-weighted contrast caused by Mn in the 
brain remains to be explored. GABA concen-
trations in these three subjects varied consider-
ably, from the highest GABA level measured in 
all subjects to lower values (2.0 mM, 1.2 mM, 
and 1.6 mM, using method 1).
Conclusions
We present for the first time in vivo quantifica-
tion of GABA in Mn-exposed workers and 
show a significant, almost 2-fold increase in 
GABA levels compared with control subjects 
in a brain region containing the thalamus 
and parts of the basal ganglia. The fact that 
GABA levels seem to be largely independent 
of the MRI signal hyperintensity associated 
with Mn deposition in MRI images, and the 
finding that NAA decreases with exposure in 
the frontal cortex, where less Mn accumulates 
than in basal ganglia structures, both support 
the notion suggested by Burton and Guilarte 
(2009) that it is the intrinsic vulnerability to 
injury by Mn rather than the amount of accu-
mulated Mn in the brain that defines its neuro-
toxicity. Because elevated GABA levels mirror 
findings in PD, and decreased NAA levels cor-
roborate neuro  degenerative changes (or at least 
neuronal dysfunction) observed in non  human 
primates, these findings may lead to a novel 
approach in identifying early presymptom-
atic pathogenic effects of Mn exposure. Larger 
sample sizes and longitudinal studies will be 
needed to further validate these results.
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